Three New Studies: TrialNet19, CIT-01, and CureGNAt NIDDK Central Repository
Here is the news from NIDDK Central Repository:
"NIDDK Central Repository announced that three new studies, ATG-GCSF in New Onset Type 1 Diabetes (TN19), Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation (CIT-01), Cure Glomerulonephropathy (CureGN), have been posted to the NIDDK Central Repository and is available for request.
TN19 was a three-arm, 1:1:1 randomized, placebo controlled, double-blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects will receive ATG alone and at least 28 subjects will receive placebo alone within 100 days from diagnosis of Type 1 Diabetes (T1D). TrialNet researchers were testing whether ATG used alone or in combination with GCSF will help people continue to make some of their own insulin.
CIT01 participants were randomized to study treatment including Low Molecular Weight Sulfated Dextran (LMW-DS) and study treatment without LMW-DS.The primary objective of this study was to evaluate the safety and efficacy of Low Molecular Weight Dextran Sulfate (LMW-DS) to enhance engraftment and prevent IBMIR in islet transplantation to Type 1 diabetic subjects. The secondary objective was to gather additional safety and efficacy information about the combination of Low Molecular Weight Sulfated Dextran with islet transplantation.
Cure Glomerulonephropathy Network (CureGN) is a multi-center consortium that seeks to establish an infrastructure for the advancement of glomerular disease studies. CureGN recruits and maintains a large and diverse population of glomerular disease patients. The study established a database of patients diagnosed with the following conditions: minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and immunoglobulin A nephropathy (IgAN)."